Evidence map›Paper›PMID 25008456›Full record

ArticleBioorganic & medicinal chemistry letters2014

Design and synthesis of new 7-(N-substituted-methyl)-camptothecin derivatives as potent cytotoxic agents.

Xiao-Bo Zhao, Masuo Goto, Zi-Long Song, Susan L Morris-Natschke, Yu Zhao, Dan Wu, Liu Yang, Shu-Gang Li, Ying-Qian Liu, Gao-Xiang Zhu and 2 more

Open access · greenAbstract read
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Xiao-Bo ZhaoSchool of Pharmacy, Lanzhou University, Lanzhou 730000, PR China.
Masuo GotoNatural Products Research Laboratories, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, United States.
Zi-Long SongSchool of Pharmacy, Lanzhou University, Lanzhou 730000, PR China.
Susan L Morris-NatschkeNatural Products Research Laboratories, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, United States.
Yu ZhaoNatural Products Research Laboratories, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, United States.
Dan WuSchool of Pharmacy, Lanzhou University, Lanzhou 730000, PR China.
Liu YangEnvironmental and Municipal Engineering School, Lanzhou Jiaotong University, Lanzhou 730000, PR China.
Shu-Gang LiSchool of Pharmacy, Lanzhou University, Lanzhou 730000, PR China.
Ying-Qian LiuSchool of Pharmacy, Lanzhou University, Lanzhou 730000, PR China. Electronic address: yqliu@lzu.edu.cn.
Gao-Xiang ZhuSchool of Pharmacy, Lanzhou University, Lanzhou 730000, PR China.
Xiao-Bing WuSchool of Pharmacy, Lanzhou University, Lanzhou 730000, PR China.
Kuo-Hsiung LeeNatural Products Research Laboratories, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, United States; Chinese Medicine Research and Development Center, China Medical University and Hospital, Taichung, Taiwan. Electronic address: khlee@email.unc.edu.
Lanzhou University · CNUniversity of North Carolina at Chapel Hill · USChina Medical University · TWLanzhou Jiaotong University · CN

Funding

Novel Antitumor AgentsR01CA177584 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LEE, KUO-HSIUNG · 2013 to 2017
$1.9M
NCI NIH HHS CA177584NCI NIH HHS R01 CA177584
6 · The paper itself

Abstract

A series of novel 7-(N-substituted-methyl)-camptothecin derivatives was designed, synthesized, and evaluated for in vitro cytotoxicity against four human tumor cell lines, A-549, MDA-MB-231, KB, and KBvin. All of the derivatives showed promising in vitro cytotoxic activity against the tested tumor cell lines, with IC50 values ranging from 0.0023 to 1.11 μM, and were as or more potent than topotecan. Compounds 9d, 9e, and 9r exhibited the highest antiproliferative activity among all prepared derivatives. Furthermore, all of the compounds were more potent than paclitaxel against the multidrug-resistant (MDR) KBvin subline. With a concise efficient synthesis and potent cytotoxic profiles, especially significant activity towards KBvin, compounds 9d, 9e, and 9r merit further development as a new generation of camptothecin-derived anticancer clinical trial candidates.

Indexed as

Drug DesignAntineoplastic AgentsCamptothecinCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansKB CellsMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsCamptothecinAntiproliferative activityCamptothecinMultidrug resistance

Identifiers

PMID25008456
PMCPMC4130764
OpenAlexW1998305595

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.